Results 21 to 30 of about 1,476,150 (337)
Small extracellular vesicle-mediated ITGB6 siRNA delivery downregulates the αVβ6 integrin and inhibits adhesion and migration of recipient prostate cancer cells
Cancer Biology & Therapy, 2022 The αVβ6 integrin, an epithelial-specific cell surface receptor absent in normal prostate and expressed during prostate cancer (PrCa) progression, is a therapeutic target in many cancers.Shiv Ram Krishn, Vaughn Garcia, Nicole M. Naranjo, Fabio Quaglia, Christopher D. Shields, Maisha A. Harris, Andrew V. Kossenkov, Qin Liu, Eva Corey, Dario C. Altieri, Lucia R. Languino +10 moredoaj +1 more sourceWNT signalling in prostate cancer [PDF]
, 2017 Genome sequencing and gene expression analyses of prostate tumours have highlighted the potential importance of genetic and epigenetic changes observed in WNT signalling pathway components in prostate tumours-particularly in the development of castration-A Ghoshal, A Gurney, A Jimeno, A Klaus, A Mallinger, A Mikels, A Säfholm, A Säfholm, AB El-Khoueiry, AC Vidal, AD,MR Kohn, AH Nile, AL Giraudet, AS Khaja, AS Perry, ASS Khaja, B Bilir, B Chen, B Madan, B Madan, BJ Feldman, BT MacDonald, C Fukukawa, C Lin, C Liu, C Liu, C Logan, C Niehrs, CL Chen, CM Cruciat, CS Grasso, CY Janda, D Grandy, D Robinson, D Zheng, DS Yee, DT Miyamoto, E Lee, E Lee, E Sandsmark, EE Storm, F Janku, F Ma, FC Gonsalves, G Chen, G O'Hurley, G Schulte, G Wang, GT Lee, H Beltran, H Clevers, H Hanaki, H Kimura, H Kumon, H Kumon, H Peradziryi, H Yamamoto, H Zhu, H-X Hao, HW Park, HX Hao, I Bisson, J Chinison, J Green, J Hao, J Liu, J Veeck, J Weischenfeldt, J-H Geng, JC Brase, JC Francis, JN Anastas, JP Dijksterhuis, JR Packer, K Ahmed, K Shojima, KC Valkenburg, KD Proffitt, KE Livermore, KH Emami, L Azzolin, L Fang, L Wu, L Zheng, LE Pascal, M Bordonaro, M Cojoc, M de la Roche, M Kahn, M Mancini, M Mazon, M Volante, M Yang, MD Shultz, MT Veeman, N Borcherding, N Li, N Takebe, NK Thudi, NN Yokoyama, O Dakhova, P Bovolenta, P García-Tobilla, P Le, P Polakis, P Rajan, P Uysal-Onganer, P Uysal-Onganer, PA Watson, R Eferl, R Kolb, R Siegel, R van Amerongen, R van Amerongen, RE O'Cearbhaill, RM Kypta, Robert Kypta, S Gupta, S Josson, S Martinez, S Perner, S Piccolo, S Takahashi, S Terry, S Thiele, S Thiele, S Zhang, S-P Huang, SA Tomlins, SH Lee, SJ Cooper, SJ Hotte, SJ Jung, SP Acebron, SP Acebron, T Chandrasekar, T Haikarainen, T Karantanos, T Malinauskas, T Phesse, TD Rachner, TM Bauman, TS Gujral, V Teneggi, Virginia Murillo-Garzón, W Lu, W Lu, W Tian, W Wang, X Chen, X Jiang, X Li, X Varelas, Y Eun-Jin, Y Kawano, Y Komiya, Y Li, Y Sun, Y Sun, Y Xie, Y Yang, Y Zhou, Y Zong, Z Debebe, Z Steinhart, ZG Li, ZJ Debruine +166 morecore +2 more sourcesTOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. [PDF]
, 2017 Purpose: Current clinical parameters do not stratify indolent from aggressive prostate cancer. Aggressive prostate cancer, defined by the progression from localized disease to metastasis, is responsible for the majority of prostate cancer–associated ...Alshalalfa, Mohammed, Bowden, Michaela, Brown, Myles, Davicioni, Elai, Den, Robert B., Ellis, Leigh, Eng, Kevin H., Erho, Nicholas, Feng, Felix Y., Galbo, Phillip, Goodrich, David W., Gray, Kathryn P., Huang, Ying, Jenkins, Robert B., Karnes, R. Jeffrey, Ku, Sheng-Yu, Labbé, David P., Rosario, Spencer, Ross, Ashley E., Schaeffer, Edward M., Sjöström, Martin, Spratt, Daniel E., Sweeney, Christopher J., Wadosky, Kristine M. +23 morecore +2 more sourcesProstate sarcoma
IJU Case Reports, 2023 IntroductionThis report is intended to provide insight into the presentation, diagnosis, and treatment of prostatic sarcomas. A literature review is included to compare variables in demographics, histology, prognosis, and treatment strategies among previously reported incidences.Case presentationIn this case, we have a 72‐year‐old man who initially ...Nicholas T Ehat, Lisa Chuong, Jenna Dickman, Tom Deng, George Chang, Jonathan Hwang +5 moreopenaire +3 more sourcesAge and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer. [PDF]
, 2016 A single early prostate-specific antigen (PSA) level has been correlated with a higher likelihood of prostate cancer diagnosis and death in younger men. PSA testing in older men has been considered of limited utility.Karnes, R Jeffrey, Kattan, Michael W, MacKintosh, F Roy, Morrell, Christopher H, Nawaf, Cayce B, Neville, Thomas B, Rawson, Lori, Sprenkle, Preston C, Walter, Louise C +8 morecore +1 more sourceProtocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours
BMC Cancer, 2018 Background Bleomycin, etoposide, and cisplatin (BEP) chemotherapy administered every 3 weeks for 4 cycles remains the standard first line treatment for patients with intermediate- and poor-risk metastatic germ cell tumours (GCTs).Nicola J. Lawrence, Howard Chan, Guy Toner, Martin R. Stockler, Andrew Martin, Sonia Yip, Nicole Wong, Annie Yeung, Danish Mazhar, Farzana Pashankar, Lindsay Frazier, Ray McDermott, Roderick Walker, Hsiang Tan, Ian D. Davis, Peter Grimison, on behalf of ANZUP +16 moredoaj +1 more sourceTwo-year quality of life after robot-assisted radical prostatectomy according to pentafecta criteria and cancer of the prostate risk assessment (CAPRA-S)
Scientific Reports, 2022 The quality of life (QoL) of men with optimal outcomes after robot-assisted radical prostatectomy (RARP) is largely unexplored. Thus we assessed meaningful changes of QoL measured with the EORTC QLQ-C30 24 months after RARP according to postsurgical ...Theodoros Karagiotis, Jorn H. Witt, Thomas Jankowski, Mikolaj Mendrek, Christian Wagner, Andreas Schuette, Nikolaos Liakos, Pawel Rachubinski, Katarina Urbanova, Matthias Oelke, Mykyta Kachanov, Sami-Ramzi Leyh-Bannurah +11 moredoaj +1 more sourceSalvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes
BMC Urology, 2022 Background To report the feasibility, oncological and functional outcomes of salvage robot-assisted radical prostatectomy (sRARP) for recurrent prostate cancer (PCa) after irreversible electroporation (IRE).Alexandar Blazevski, William Gondoputro, Matthijs J. Scheltema, Amer Amin, Bart Geboers, Daniela Barreto, Anne-Maree Haynes, Ron Shnier, Warick Delprado, Shikha Agrawal, James E. Thompson, Phillip D. Stricker +11 moredoaj +1 more sourceMechanisms of growth inhibition of primary prostate epithelial cells following gamma irradiation or photodynamic therapy including senscence, necrosis, and autophagy, but not apoptosis [PDF]
, 2015 In comparison to more differentiated cells, prostate cancer stem-like cells are radioresistant, which could explain radio-recurrent prostate cancer. Improvement of radiotherapeutic efficacy may therefore require combination therapy.Boyle, Ross W., Bryden, Francesca, Frame, Fiona M., Giuntini, Francesca, Maitland, Norman J., Mann, Vincent M., Savoie, Huguette, Simms, Matthew S. +7 morecore +1 more sourceA generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes
npj Precision Oncology, 2023 Specific classes of DNA damage repair (DDR) defect can drive sensitivity to emerging therapies for metastatic prostate cancer. However, biomarker approaches based on DDR gene sequencing do not accurately predict DDR deficiency or treatment benefit ...Elie J. Ritch, Cameron Herberts, Evan W. Warner, Sarah W. S. Ng, Edmond M. Kwan, Jack V. W. Bacon, Cecily Q. Bernales, Elena Schönlau, Nicolette M. Fonseca, Veda N. Giri, Corinne Maurice-Dror, Gillian Vandekerkhove, Steven J. M. Jones, Kim N. Chi, Alexander W. Wyatt +14 moredoaj +1 more source
